ezetimibe / Generic mfg. - LARVOL DELTA

Consistency over intensity: atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in ACS patients: a comparative study of efficacy, tolerability, and cardiovascular outcomes. (PubMed, Egypt Heart J) - "Atorvastatin 40 mg plus ezetimibe 10 mg demonstrated superior LDL-C reduction, improved tolerability, and fewer MACE compared to atorvastatin 80 mg monotherapy in ACS patients. These findings support the use of combination therapy as a viable starting alternative to atorvastatin 80 mg monotherapy following ACS, particularly in patients likely to have statin intolerance."

Journal • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia • Metabolic Disorders • Pain

Clinical Response to Elevated Lipoprotein(a): Practical Approach for Risk Management in the Absence of Targeted Therapies. (PubMed, Semin Thromb Hemost) - "Statins, ezetimibe, bempedoic acid and lifestyle interventions have little or no effect on Lp(a). Statins may modestly raise levels, niacin is now contraindicated as it has not been shown to reduce cardiovascular or all-cause mortality, while PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) inhibitors and inclisiran reduce Lp(a) concentrations by ~20-30%, though this effect remains secondary to their LDL-C lowering effect...Future promise lies in RNA-based therapies, including antisense oligonucleotides (pelacarsen) and small-interfering RNAs (olpasiran, lepodisiran, SLN360), which achieve 80-95% sustained Lp(a) reductions...High or extreme elevations, especially with ASCVD, mandate aggressive LDL-C lowering, optimization of modifiable risk factors, family cascade screening, and apheresis or referral to RNA-therapy trials in select cases. Thus, while therapeutic options remain limited, systematic measurement and risk stratification are ethically justified to prepare..."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia

HMGCR-related SNPs and cholelithiasis: statins may exert effects beyond lipid-lowering. (PubMed, Postgrad Med J) - "These facts shows that statins are associated with a decreased risk of cholelithiasis, and this association is unlikely to be mediated by lipid-lowering effects. Further clinical trials and basic experimental validation is needed to validate their relationship and underlying mechanisms."

Journal • Dyslipidemia • Gastroenterology

Safety outcomes of statin vs non-statin lipid-lowering interventions in patients with prior statin-associated muscle symptoms: A systematic review and meta-analysis. (PubMed, PLoS One) - "Our findings suggest that patients with a history of SAMS can be re-challenged with statins. More high-quality evidence is needed to strengthen guidelines regarding the management of SAMS."

Clinical • Journal • Retrospective data • Review • Cardiovascular

Current Status and Clinical Characteristics of Familial Hypercholesterolemia Patients in Korea: A Multicenter, Real-World Experience. (PubMed, Diagnostics (Basel)) - "A high proportion of patients were treated with statins (80.2%) and ezetimibe (64.9%), but the use of proprotein convertase subtilisin/kexin type 9 inhibitors was low (11.7%)... FH is frequently diagnosed late after the onset of clinical ASCVD and is undertreated, although recent trends show improvement. Our results again underline the need for proper screening and identification of patients with FH."

Journal • Real-world evidence • Atherosclerosis • Cardiovascular • Dyslipidemia • Endocrine Disorders • Familial Hypercholesterolemia • Genetic Disorders • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • APOB • PCSK9

ESC guidelines on dyslipidemia update 2025 : New recommendations for the practice (PubMed, Herz) - "A major focus is on the acute coronary syndrome: the immediate initiation of high-intensity statin treatment, mostly in combination with ezetimibe is recommended...The use of dietary supplements and vitamins for prevention, however, are discouraged. The update reinforces the principle of risk-adapted LDL‑C target values, expands the treatment options and emphasizes the need for early, consistent lipid-lowering with practical recommendations."

Journal • Review • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders

Indications of Bempedoic Acid. (PubMed, Cardiol Rev) - "Randomized controlled trials demonstrate LDL-C reductions of 15-20% with monotherapy and up to 40% with ezetimibe combination, alongside cardiovascular event reduction in statin-intolerant patients. Regulatory approvals in the United States, European Union, and United Kingdom converge on its role in patients unable to tolerate statins or inadequately controlled on standard therapy. This review synthesizes current evidence and guideline positioning, situating bempedoic acid within contemporary lipid management strategies that emphasize earlier combination therapy, achievement of lower LDL-C thresholds, and long-term maintenance of treatment goals."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia

Little Evidence of Atherosclerosis in a Middle-Aged Japanese Woman with Familial Hypercholesterolemia Carrying PCSK9 (p.Glu32Lys) and ABCG8 (p.Ile419Asn) Variants Despite Elevated Lipoprotein(a) Levels. (PubMed, Intern Med) - "Combination therapy with rosuvastatin (5 mg) and ezetimibe (10 mg) lowered her LDL-C levels to approximately 70 mg/dL. This paradoxical mild atherosclerosis, despite multiple genetic and lipoprotein risks, highlights the heterogeneity of Familial Hypercholesterolemia and the utility of genotype-guided risk stratification."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders

Adherence trajectories of oral lipid-lowering therapy in patients with myocardial infarction and its estimated impact on low-density lipoprotein levels. (PubMed, Clin Res Cardiol) - "Suboptimal adherence following a treatment gap is common and has a clinically significant impact on the degree of LDL-C lowering."

Journal • Cardiovascular • Dyslipidemia • Myocardial Infarction

COAST Study - Cholesterol Optimization After Stroke (clinicaltrials.gov) - P=N/A | N=500 | Not yet recruiting | Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

New trial • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders

Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis. (PubMed, Ann Med) - "Incorporating ezetimibe with moderate-intensity statins, rather than relying solely on high-intensity statins, may reduce the risk of NO-T2DM in patients with dyslipidemia and elevated cardiovascular disease risk. CRD42024518630."

Journal • Retrospective data • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Lipid-lowering therapy and LDL cholesterol control among high- and very high-risk patients in Portugal: An analysis of the SANTORINI study. (PubMed, Rev Port Cardiol) - "The Portuguese cohort of the SANTORINI study demonstrates both encouraging developments and ongoing challenges in the real-world management of dyslipidemia following the 2019 ESC/EAS guidelines. Reasons for lack of LLT intensification and factors underlying worsening rates for LDL-C goal attainment should be explored."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders

Pharmacokinetics of a single-pill combination of rosuvastatin and ezetimibe (2.5 mg/10 mg) in healthy Chinese subjects: an open-label, two-period, phase I study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "LDL-C reached a reduction of 37.7 ± 9.0%, 44.4 ± 8.3%, and 16.0 ± 16.3% at D20, D23, and D28, respectively, compared with its level at D13 (all P < 0.05). The total adverse event (AE) rate was 81.3%, and all these AEs were Grade I. The single-pill combination of rosuvastatin and ezetimibe (2.5 mg/10 mg) indicates a steady pharmacokinetic characteristic, a good lipid-lowering effect, and a safe profile in healthy Chinese subjects."

Journal • P1 data • PK/PD data • Dyslipidemia • Metabolic Disorders

Use of cardiovascular risk scores in adult populations with cystic fibrosis (BTS WM 2025) - "However, only 9.1% were prescribed either a statin or ezetimibe...Challenges such as co-existing liver disease and polypharmacy may also influence prescribing practices. Given the evolving demographics and risk profiles of PwCF, further research is warranted to validate risk prediction tools and tailor cardiovascular risk management strategies for this unique cohort."

Clinical • Cardiovascular • Chronic Kidney Disease • Cystic Fibrosis • Diabetes • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Respiratory Diseases

Eligibility for Icosapent ethyl in patients undergoing cardiac rehabilitation: A real-world cohort study. (PubMed, Int J Cardiol) - "In a large real-world cohort of acute and chronic coronary syndrome undergoing cardiac rehabilitation, over 10 % of patients were theoretically eligible for IPE based on clinical trial criteria. However, less than 1 % met current AIFA eligibility conditions due to added restrictions, highlighting a significant barrier to implementation in clinical practice."

Journal • Real-world evidence • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia • Hypertriglyceridemia

Life Course Approach to Familial Hypercholesterolemia. (PubMed, Curr Cardiol Rep) - "Pharmacological management of FH typically involves statins and ezetimibe, as well as PCSK9 inhibitors. In the elderly, therapeutic strategies must account for age-related factors, such as frailty and comorbidities."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders

Research Status and Latest Progress in the Regulatory Mechanisms of ABCA1. (PubMed, Int J Mol Sci) - "Currently, clinical drugs for regulating cholesterol are dominated by statins, supplemented by ezetimibe, PCSK9 inhibitors, and others. However, these drugs have certain limitations, and research on ABCA1-targeted drugs is relatively scarce. Therefore, summarizing the research progress on the regulatory mechanism of ABCA1 is expected to provide important insights for the development of new therapies to maintain cholesterol homeostasis."

Journal • Review • ABCA1

Cocrystallization of Ezetimibe with Organic Acids: Stoichiometric Optimization for Improved Solubility and Bioavailability. (PubMed, Pharmaceutics) - "Benzoic acid at a 1:2 ratio via SEV demonstrated superior solubility, dissolution, and bioavailability, addressing ezetimibe's formulation challenges. These findings underscore the potential of rational cocrystal design to overcome solubility barriers in oral dosage development, particularly for hydrophobic therapeutics."

Journal • CDKN1A

Assessment of CoQ10 Dietary Intake in a Mediterranean Cohort of Familial Hypercholesterolemia Patients: A Pilot Study. (PubMed, Nutrients) - "we discussed the relevance of exogenous CoQ10 for FH development and potential SAMS. Interestingly, this information can be extrapolated to define the regular CoQ10 intake of the Spanish population, especially when following the MedDiet."

Journal • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders

Relative Efficacy of Alirocumab, Evolocumab, Inclisiran, and Bempedoic Acid on Lipids in Patients with Cardiovascular Disease or Familial Hypercholesterolaemia. (PubMed, J Clin Med) - "Methods and This observational study evaluated the impact of novel lipid-lowering therapies (alirocumab, evolocumab, inclisiran, and bempedoic acid) in patients with a history of atherosclerotic cardiovascular disease or familial hypercholesterolaemia treated with maximum-tolerated doses of high-intensity statin therapy with or without ezetimibe. Strength and limitations: This was the first study to comprehensively compare the efficacy of novel lipid-lowering therapies in achieving guideline-recommended LDL targets within a high-risk cardiovascular population. The sample size was relatively small, especially for patients treated with bempedoic acid."

Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia

Efficacy and safety of alirocumab in patients with established atherosclerotic vascular disease before the first cardiovascular event: Pooled analysis of phase 3 ODYSSEY studies. (PubMed, J Clin Lipidol) - "Among patients with ASCVD without previous ACS or stroke, alirocumab significantly reduced calculated LDL-C levels vs controls and was well tolerated."

Journal • P3 data • Retrospective data • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Metabolic Disorders • Myocardial Infarction

Residual Platelet Reactivity and Dyslipidemia in Post-CABG Patients Undergoing Repeat Revascularization: Insights from Kazakhstan. (PubMed, Diseases) - "Residual platelet reactivity and dyslipidemia are common and clinically relevant predictors of repeat revascularization after CABG. Optimization of antiplatelet and lipid-lowering therapy should be prioritized in secondary prevention for this high-risk population. These findings are particularly important in Kazakhstan, where post-CABG management strategies warrant further improvement."

Journal • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Diabetes • Dyslipidemia • Hypotension • Metabolic Disorders • Nephrology

Lipid-Lowering Therapy Is Underutilized Across LDL-C Levels in Autoimmune Disease Compared to Diabetes: A Nationwide Analysis (AHA 2025) - "Statins included atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin. Non-statin therapies included icosapent ethyl, colesevelam, alirocumab, evolocumab, Bempedoic acid, cholestyramine, Inclisiran, colestipol, ezetimibe, gemfibrozil, omega-3 acid, fenofibrate...Non-statin lipid-lowering therapy use was significantly lower in autoimmune patients compared to those with diabetes across all LDL-C tertiles, with the largest differences observed at LDL <70 mg/dL (6.19% vs 10.24%, p<0.0001) and 70–99 mg/dL (4.05% vs 7.06%, p<0.0001).ConclusionDespite comparable ASCVD risk, patients with autoimmune disease are significantly less likely to receive statins or non-statin lipid-lowering therapy than those with DM across LDL-C levels. These findings show a need for improved cardiovascular prevention in this high-risk population."

Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus

MILOS: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia (clinicaltrials.gov) - P=N/A | N=5000 | Active, not recruiting | Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Trial completion date: Sep 2025 ➔ Oct 2026 | Trial primary completion date: Sep 2025 ➔ Oct 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia

Innovative Lipid-Lowering Strategies: RNA-Based, Small Molecule, and Protein-Based Therapies. (PubMed, Endocrinol Metab (Seoul)) - "While 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, as well as ezetimibe, fibrates, and omega-3 fatty acids have established roles in lipid lowering, significant residual risk persists in many patients due to insufficient low-density lipoprotein cholesterol (LDL-C) reduction, elevated triglyceride-rich lipoproteins, and genetically determined elevations of lipoprotein(a) (Lp(a)). Clinical outcome trials have validated bempedoic acid, PCSK9 inhibitors, and icosapent ethyl, while large-scale programs are ongoing for obicetrapib, oral PCSK9 inhibitors, Lp(a)-targeted oligonucleotides, and ANGPTL3-directed RNA therapeutics. This review summarizes the mechanisms, pivotal trials, and clinical implications of innovative lipid-lowering therapies, highlighting how they may reshape future treatment algorithms for ASCVD prevention."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • ANGPTL3 • APOB